Article Text

Download PDFPDF

Ropinirole eye drops induce vomiting effectively in dogs: a randomised, double-blind, placebo-controlled clinical study
  1. Minna Suokko1,
  2. Lasse Saloranta1,
  3. Terttu Lamminen1,
  4. Tarmo Laine1 and
  5. Jonathan Elliott2
  1. 1 Department of Research and Development, Orion Pharma Orion Corporation, Espoo, Finland
  2. 2 Department of Comparative Biomedical Sciences, Royal Veterinary College, University of London, London, UK
  1. Correspondence to Dr Minna Suokko; minna.suokko{at}orionpharma.com

Abstract

There is a need for an effective and safe emetic agent that dog owners could easily administer to their dogs following veterinary advice in cases of potential poisoning. As a response to this need, a randomised, double-blind, multi-site, clinical field study was performed to assess the efficacy, safety and usability of ropinirole eye drops to induce vomiting in dogs. Ropinirole (target dose 3.75 mg/m2) was applied to eyes of 100 dogs, and 32 dogs received placebo. The drug was administered by the dog owner at a veterinary clinic under the supervision of a veterinarian and led to vomition in 95% of the ropinirole-treated dogs within 30 min. The median time to first vomit was 10 min (range: 3–37 min). None of the dogs receiving placebo vomited in this time period. All owners were able to administer the product and 96% of them assessed the administration to be very easy or easy, which was confirmed by the observing veterinarian. Some ocular signs were seen both with ropinirole and placebo, hyperaemia being the most common. All observed signs were transient and in most cases mild. Ropinirole eye drops provided an effective, safe and reliable means to induce emesis in dogs.

  • dogs
  • emesis
  • eye drops
  • toxin
  • clinical trials
  • clinical practice

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding The study was sponsored by Orion Corporation Orion Pharma. The authors thank the study team, participating investigators and dog owners.

  • Competing interests MS, LS, TL and TL are employees of Orion Corporation. JE is a paid consultant of Orion Corporation.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.